Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
Más datosThe interaction between hepatitis C and metabolic syndrome (MS) is widely discussed in the literature.
ObjectiveTo study the prevalence of MS in individuals with chronic hepatitis C and the associated clinical factors.
MethodologyThis is a cross-sectional study. The study included 334 individuals with chronic hepatitis C, in which anthropometric variables, blood pressure and results of laboratory tests were analyzed.
ResultThe prevalence of MS in patients with hepatitis C was 2.4% (8/334). The mean values of ALT were 90.1 ± 65.8; AST of 76.3 ± 70.4; and GGT of 130.2 ± 160, among those with HCV infection without MS. Among individuals with MS, ALT was 122.3 ± 82.3, AST was 76.7 ± 29.5, GGT was 102.3 ± 55.2. The steatosis found was 49.7% (166/334), while among individuals with MS, a frequency of 62.5% (5/8) was observed. F1 was 23.8% in HCV patients and, in SM, it was 12.5%; F2 48.5% and 37.5%, F3 22% and 37.5% and F4 5.7% and 12.5%. In individuals with hepatitis C and MS, systemic arterial hypertension was observed in 87.5% of cases, diabetes in 75%, dyslipidemia in 62.5% and obesity.
ConclusionMS had a low prevalence in HCV patients, and was associated, with a higher frequency of steatosis, greater inflammatory activity and more advanced liver fibrosis.